Numinus Wellness Inc (NUMIF) Fair Value & Analysis
Healthcare · US · Market cap $11.9M
Numinus Wellness Inc
NUMIF · US
Risks
Fair value as of: Aug 20, 2026
From 1 valuation models · updated yesterday
Share price −29.8% over the past month.
Below-average quality, and screening another 27% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0255). The favourable scenario is already priced in.
- Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range $0.0060 – $0.8951 · the $0.0351 price screens above the $0.0255 fair value. Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Numinus Wellness Inc (NUMIF) currently trades at $0.0351, while our model-based Fair Value estimate is $0.0255, implying the stock looks roughly 27.4% overvalued today. The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $6.5M. Revenue grew 81.6% year over year. Fundamentals as of Aug 20, 2026
The share trades about 37% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at -27%, NUMIF screens cheaper than that median.
Notify me when NUMIF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies.
Full company description
Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to support clinical trials and commercialization efforts. Numinus Wellness Inc. is headquartered in Vancouver, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Numinus Wellness Inc reported revenue of $4.2M in FY2024 versus $881K in FY2020, a compound +47.5%/yr. Reported net income was −$19.6M in FY2024.
NUMIF screens 27% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.09 | R$47.31 | +43% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | -66% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.40 THB | 18.57 THB | -4% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare Numinus Wellness Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Numinus Wellness Inc (NUMIF) overvalued or undervalued?
What is the fair value of NUMIF?
What is the quality score of NUMIF?
What is the revenue of Numinus Wellness Inc (NUMIF)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Numinus Wellness Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.